Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 6/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21805031 | 0.90 | HDAC4 (0.45) | HDAC4LMNAOPRL1 | |
| SCHEMBL30088123 | 0.90 | HDAC4 (0.45) | HDAC4LMNAOPRL1 | |
| SCHEMBL333238 | 0.80 | OPRL1 (0.36) | HDAC4ALOX5ALDH1A1LMNATSHR | |
| SCHEMBL30991214 | 0.75 | HDAC4 (0.46) | HDAC4 | |
| SCHEMBL18742673 | 0.72 | HDAC4 (0.62) | HDAC4LMNAOPRL1 | |
| SCHEMBL1628115 | 0.72 | HDAC4 (0.54) | HDAC4ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL2702973 | 0.71 | ALOX5 (0.50) | ALOX5ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL333096 | 0.71 | PDE1A (0.32) | HDAC4ALDH1A1 | |
| SCHEMBL17025863 | 0.71 | HDAC3 (0.46) | HDAC4OPRL1 | |
| SCHEMBL2702113 | 0.71 | OPRL1 (0.45) | HDAC4OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | HDAC4 3124/4885ALOX5 1/4885ALDH1A1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.